– Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease –– IW-6463 translational […]
– Strong global pipeline progress – three U.S. FDA1Fast Track Designations; surufatinib U.S. NDA2preparations underway; and initiation of global Phase […]